Extension Program for Bay 43-9006
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.
Neoplasm|Metastasis
DRUG: Nexavar (Sorafenib, BAY43-9006)
Survival, Death
Objective Tumour Response Rate, Number of confirmed partial and complete responses|Overall Response Duration, Time from the date of the first intake of sorafenib to the date that progressive disease is documented.|Time to Objective Response, Time from the date of the first intake of sorafenib to the date that objective response is first documented.|Time to Disease Progression, Time from first intake of sorafenib to disease progression|Safety Parameters, Throughout study
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.